296 related articles for article (PubMed ID: 15748287)
21. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation.
King JT; Tsevat J; Lave JR; Roberts MS
Med Decis Making; 2005; 25(6):667-77. PubMed ID: 16282217
[TBL] [Abstract][Full Text] [Related]
22. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?
Braithwaite RS; Meltzer DO; King JT; Leslie D; Roberts MS
Med Care; 2008 Apr; 46(4):349-56. PubMed ID: 18362813
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the EuroQol and short form 6D in Singapore multiethnic Asian knee osteoarthritis patients scheduled for total knee replacement.
Xie F; Li SC; Luo N; Lo NN; Yeo SJ; Yang KY; Fong KY; Thumboo J
Arthritis Rheum; 2007 Aug; 57(6):1043-9. PubMed ID: 17665466
[TBL] [Abstract][Full Text] [Related]
24. Comparison of measured utility scores and imputed scores from the SF-36 in patients with rheumatoid arthritis.
Kaplan RM; Groessl EJ; Sengupta N; Sieber WJ; Ganiats TG
Med Care; 2005 Jan; 43(1):79-87. PubMed ID: 15626937
[TBL] [Abstract][Full Text] [Related]
25. Sample size and power estimation for studies with health related quality of life outcomes: a comparison of four methods using the SF-36.
Walters SJ
Health Qual Life Outcomes; 2004 May; 2():26. PubMed ID: 15161494
[TBL] [Abstract][Full Text] [Related]
26. The impact of differences in EQ-5D and SF-6D utility scores on the acceptability of cost-utility ratios: results across five trial-based cost-utility studies.
Joore M; Brunenberg D; Nelemans P; Wouters E; Kuijpers P; Honig A; Willems D; de Leeuw P; Severens J; Boonen A
Value Health; 2010; 13(2):222-9. PubMed ID: 19878492
[TBL] [Abstract][Full Text] [Related]
27. An economic analysis of outcomes and complications of treating distal radius fractures in the elderly.
Shauver MJ; Clapham PJ; Chung KC
J Hand Surg Am; 2011 Dec; 36(12):1912-8.e1-3. PubMed ID: 22123045
[TBL] [Abstract][Full Text] [Related]
28. Does combining antiretroviral agents in a single dosage form enhance quality of life of HIV/AIDS patients? A cost-utility study.
Ganguli A; Wang J; Gourley DR
Res Social Adm Pharm; 2012; 8(2):157-65. PubMed ID: 21712147
[TBL] [Abstract][Full Text] [Related]
29. Relationship between quality of life instruments, health state utilities, and willingness to pay in patients with asthma.
Blumenschein K; Johannesson M
Ann Allergy Asthma Immunol; 1998 Feb; 80(2):189-94. PubMed ID: 9494453
[TBL] [Abstract][Full Text] [Related]
30. Cost-utility analysis of contaminated appendectomy wounds.
Brasel KJ; Borgstrom DC; Weigelt JA
J Am Coll Surg; 1997 Jan; 184(1):23-30. PubMed ID: 8989296
[TBL] [Abstract][Full Text] [Related]
31. Rating of arthritis health states by patients, physicians, and the general public. Implications for cost-utility analyses.
Suarez-Almazor ME; Conner-Spady B
J Rheumatol; 2001 Mar; 28(3):648-56. PubMed ID: 11296976
[TBL] [Abstract][Full Text] [Related]
32. A new and more robust test of QALYs.
Doctor JN; Bleichrodt H; Miyamoto J; Temkin NR; Dikmen S
J Health Econ; 2004 Mar; 23(2):353-67. PubMed ID: 15019761
[TBL] [Abstract][Full Text] [Related]
33. Using patients as their own controls for cost evaluation of phase I clinical trials.
Sherman EJ; Rubin DM; Venkatraman E; Schwartz GK; Miller VA; Radzyner MH; Ruchlin HS; Spriggs D; Pfister DG
J Clin Oncol; 2004 Apr; 22(7):1308-14. PubMed ID: 15051779
[TBL] [Abstract][Full Text] [Related]
34. Calculation of quality adjusted life years in the published literature: a review of methodology and transparency.
Richardson G; Manca A
Health Econ; 2004 Dec; 13(12):1203-10. PubMed ID: 15386669
[TBL] [Abstract][Full Text] [Related]
35. Estimation and comparison of derived preference scores from the SF-36 in lung transplant patients.
Lobo FS; Gross CR; Matthees BJ
Qual Life Res; 2004 Mar; 13(2):377-88. PubMed ID: 15085910
[TBL] [Abstract][Full Text] [Related]
36. Health outcomes in economic evaluation: the QALY and utilities.
Whitehead SJ; Ali S
Br Med Bull; 2010; 96():5-21. PubMed ID: 21037243
[TBL] [Abstract][Full Text] [Related]
37. Willingness to pay for a QALY.
Gyrd-Hansen D
Health Econ; 2003 Dec; 12(12):1049-60. PubMed ID: 14673813
[TBL] [Abstract][Full Text] [Related]
38. Healthy-year equivalents in major joint replacement. Can patients provide meaningful responses?
Llewellyn-Thomas HA; Arshinoff R; Bell M; Williams JI; Naylor CD
Int J Technol Assess Health Care; 2002; 18(3):467-84. PubMed ID: 12391941
[TBL] [Abstract][Full Text] [Related]
39. Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure.
Alkhatib N; Sweitzer NK; Lee CS; Erstad B; Slack M; Gharaibeh M; Karnes J; Klimecki W; Ramos K; Abraham I
Am J Cardiovasc Drugs; 2021 Mar; 21(2):205-217. PubMed ID: 32710439
[TBL] [Abstract][Full Text] [Related]
40. [Benefits, costs and analysis in diagnostic radiology: definitions and glossary].
Golder W
Rofo; 1999 Jan; 170(1):73-9. PubMed ID: 10071648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
